-
Incyte conducts its first patient treatment in a phase III clinical trial of ruxolitinib cream treatment
Time of Update: 2020-06-08
Recently, Incyte (http:// announced that the first patient has been treated in the Phase III TRuE-V Clinical Trial (http:// project to evaluate the treatment of vitiligo in the ruxolitinib cre
-
AstraZeneca announces results of Phase 3 clinical trial sedaton and aspirin combination
Time of Update: 2020-06-08
recently (September 3) AstraZeneca (http:// published detailed results of phase 3 clinical trial (http:// THEMIS results showed that a combination of ticagrelor and aspirin combined with aspi
-
Twenty scientific research institutions gather edgy at The 2019 Shanghai Biofermentation Exhibition
Time of Update: 2020-06-08
, this exhibition will gather 2000 biofermentation research institutions to participate in the industry to bring the latest research results, production processes, technical problems to answer, for the biofermentation industry escort!
-
FDA accepts biologics license application for Mercado-Ontom Ebola vaccine V920
Time of Update: 2020-06-08
Today, http:// the http:// of the U.S FDA (http:// ) has accepted an application for a biologic license (BLA ) for its Ebola vaccine to prevent disease caused by the Ebola virus, the http:// htt
-
Clinuvel's Scenese (afamelanotide) is approved for listing by FDA
Time of Update: 2020-06-08
recently, the u.S FDA (http:// announced the approval of Clinuvel (http:// development of Scenesse (http:// to treat adult patients with skin damage caused by red blood cell-generating protosi
-
Sansheng Pharmaceutical monoclonal antibody injection (608) clinical trial application approved
Time of Update: 2020-06-08
Recently, China's leading bio pharmaceutical (http:// company (http:// Sansheng Pharmaceuticals (01530 HK) announced that its self-developed redeveloped recombinant humanized anti-white-17A mon
-
FDA approves Lilly Reyvow tablets to be available for treatment in adult migraine sufferers
Time of Update: 2020-06-08
today, Lilly (http:// announced that the U.S FDA (http:// approved the company's development of Reyvow tablets as an early or no-foreboding adult migraine treatment for acute treatment About
-
Sinlita Omesatan tablets (Sinda Yue ®) approved by the State Drug Administration
Time of Update: 2020-06-08
Recently, Xinlitai issued a notice that the Company (http:// received the National Drug (http:// Supervision Authority approved the issuance of the Omesatan tablets (Sinda Yue ®) "Drug Registr
-
Novartis CD20 Antibody ofatumumab reaches major end in Phase 3 clinical trial streats on RMS patients
Time of Update: 2020-06-08
MS is a chronic disease of the central nervous system (CNS), which disrupts the normal function of the brain, optic nerve and spinal cord through inflammation and tissue damage Novartis (http://
-
The extended indications of the ® of The Pharmaceutical Administration of China have been approved by the State Drug Administration of China
Time of Update: 2020-06-08
recently, Baishi Meishi Guibao announced that its PD-1 inhibitor Odivo ® (Navuliyu monoantigen) has been approved by China's National Drug (http:// Regulatory Authority to expand the indications
-
Novartis adult migraine erenumab injection approved by the National Drug Administration
Time of Update: 2020-06-08
Recently, the (http:// of Novartis (China) Biomedical Research Company was granted an adaffle by the State Drug Administration's Clinical Trial (http:// ) the erenumab injection for the preven
-
Mallinckrodt's terlipressin key phase 3 test CONFIRM reaches major and secondary endpoints
Time of Update: 2020-06-08
recently, (http:// of the http:// company of Mallinckrodt Bio Medicine sin announced that its terlipressin had reached the main and all secondary end points of the trial in the key phase 3 tria
-
Azurity launches Katerzia oral fluid in U.S. market
Time of Update: 2020-06-08
recently, Azurity Pharmaceuticals company (http:// announced the introduction of Katerzia (amlodipine, amchloride) oral suspension (1mg/mL) in the U.S market Katerzia oral fluid spout is suitabl
-
European Commission grants SpringWorks company mirdametinib orphan drug for neurofibromatosis type 1
Time of Update: 2020-06-08
The European Commission (EC) has granted mirdametinib (formerly PD-0325901) the right to treat neurofibromatosis type 1 (NF1), springWorks company (http:// announced About mirdametinib mirdame
-
Lilly Pharmaceuticals ® (Edge Pearl Mono-Injection) obtains listing approval from the State Drug Administration
Time of Update: 2020-06-08
yesterday (September 4), Lilly Pharmaceutical (http:// (China) announced that the Tudor ® (Ichizhu mono-injection) for the treatment of patients with moderate to severe plaque psoriasis suitable
-
Puma Biotechnology's Nerinib approved for extended complementary treatment for early stage breast cancer patients
Time of Update: 2020-06-08
recently, the (http:// of the http:// announced by the of the http:// of medicines and, the argentine Medicines (http:// , food and medical device s (http:// Agency has approved Nerlynx for
-
AstraZeneca and Mersadon release Phase III clinical study data for targeted cancer drug Lynparza
Time of Update: 2020-06-08
Recently, AstraZeneca and partner Mersadon released positive data on the evaluation of phase III clinical research PROfound, a targeted cancer drug, Lynparza (Lipjo, olaparib, ) This assessment was
-
New auxiliary treatment approved for patients with stage IIIA non-small cell lung cancer approved by Junshi Bio Treplymono
Time of Update: 2020-06-07
Recently, according to relevant news, Junshi bio-Treplymono-approved clinical, for combined chemotherapy in the resectionable phase IIIA non-small cell lung cancer patients of the new auxiliary trea
-
Wessa launches new Parkinson's disease drug Equfina 50mg tablet splicing in Japan
Time of Update: 2020-06-07
recently, Japanese drugmaker Atva announced the launch of the new drug (http:// in Japan Equfina 50mg tablets (safinamide, safenamide) Equfina was approved in Japan in September to improve effic
-
FDA approves Alnylam's RNAi drug givlaari (givosiran) for the treatment of acute hepatic rickets
Time of Update: 2020-06-07
The u.S Food and Drug (http:// Administration (http:// has approved another of its RNAi drug, Givlaari (givosiran), which is given through subcutaneous injections to treat adult patients with a
